iRhythm Holdings, Inc.

iRhythm Holdings, Inc. (Nasdaq: IRTC) is a leading digital healthcare company that designs, develops, and commercializes device-based technology to provide ambulatory cardiac monitoring services. The company's website is https://www.irhythmtech.com.

iRhythm's principal business centers on its iRhythm ACM Systems, which combine wire-free, patch-based, 14-day wearable biosensors with proprietary cloud-based data analytics software to help physicians monitor patients and diagnose cardiac arrhythmias. The company offers three iRhythm ACM System options: the Zio monitor System, the Zio XT System, and the Zio AT System. These systems deliver continuous electrocardiogram data collection with high patient compliance rates between 98 and 99 percent, enabling physicians to diagnose arrhythmias more efficiently than traditional monitoring technologies.

The company provides ambulatory cardiac monitoring services through Medicare-enrolled independent diagnostic testing facilities, including long-term continuous monitoring services and mobile cardiac telemetry monitoring services. Since receiving FDA clearance in 2009, iRhythm has provided services via more than twelve million patient reports and collected almost three billion hours of curated heartbeat data. The company holds approximately 40 percent penetration of the core ambulatory cardiac monitoring market in the United States and delivers more than 70 percent of long-term continuous monitoring services nationally as of 2025.

iRhythm employs approximately 2,400 regular full-time employees as of December 31, 2025. The company manufactures its iRhythm ACM Systems in a leased facility in Cypress, California. Internationally, iRhythm has established commercial presence in the United Kingdom, selected European countries, and Japan.

The company's strategy focuses on leading and expanding within the core ambulatory cardiac monitoring market, unlocking market expansion through access and evidence-based approaches, pursuing international expansion opportunities, extending the Zio platform into adjacent clinical opportunities such as obstructive sleep apnea and heart failure patients, and advancing its product portfolio and technology platform. iRhythm's competitive advantages include its proprietary deep-learned artificial intelligence algorithms, extensive clinical evidence base, patient-friendly device design, and integrated digital workflows that support physician decision-making.